PROSTAGLANDIN MARKET REPORT OVERVIEW
- Request a Free sample to learn more about this report
The global prostaglandin market size was USD 520.6 million in 2022 and is expected to reach USD 965.22 million in 2031, exhibiting a CAGR of 7.1% during the forecast period.
Prostaglandin is a type of lipid which are produced at the site where they are needed in the body. Although they might seem like hormones, their functioning is different from other hormones. Other hormones are produced by glands and transferred by the bloodstream to various parts of the body. Prostaglandin helps the body in dealing with injuries and illnesses. Whenever a part of the body gets injured, prostaglandin is produced at the site. The healing process involves pain, fever, or inflammation.
Apart from its function of dealing with injuries, it also regulates the contraction and relation of muscles in the gut and in the respiratory system. In the female body, prostaglandin regulates the reproductive system. It does so by maintaining the menstrual cycle and controlling ovulation. They also aid in inducing labor during pregnancy. Other effects of prostaglandin include reducing the amount of acid in the stomach and aiding in blood clotting. Prostaglandins are also used in the treatment of glaucoma and other ophthalmologic diseases. Their veterinary use includes smoothening and controlling the reproductive processes in domestic animals such as cattle, sheep, and horses.
COVID-19 Impact: Insufficient R&D Limited Market Potential in COVID-19 Treatment
The global COVID-19 pandemic has been unprecedented and staggering, with prostaglandin experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the prostaglandin market growth and demand returning to pre-pandemic levels once the pandemic is over.
The COVID-19 pandemic has affected all forms of healthcare. Prostaglandins are lipids that can cause inflammation, pain, and fever. They can also reduce pain and fever by being the first step in the healing process. This is why the use of prostaglandins to treat COVID-19 patients is very debatable. COVID-19 patients are prescribed non-steroidal anti-inflammatory drugs (NSAIDs) for treatment. NSAIDs are helpful in reducing fever, pain, and inflammation which are common symptoms of COVID-19 patients. These medicines perform their function by blocking prostaglandin production in the body. So, the treatment of COVID-19 patients doesn’t utilize prostaglandin. Insufficient research and clinical studies about the potential of prostaglandin in treating COVID-19 or alleviating symptoms associated with it restricted the market potential during the pandemic.
PROSTAGLANDIN MARKET SEGMENTATION
- Request a Free sample to learn more about this report
- By Type Analysis
In terms of type, the prostaglandin market can be divided into human prostaglandin and veterinary prostaglandin. The human prostaglandin segment is anticipated to dominate the prostaglandin market.
- By Application Analysis
According to application, the prostaglandin market can be bifurcated into cardiovascular, gynecological and obstetrical, ophthalmologic, and others. The cardiovascular segment is anticipated to be the leading segment in the market.
Driving Factors
"Rise in the Awareness of Female Reproductive Health to Boost Demand"
Earlier, reproductive health was considered a taboo among various sections of society. Women were shunned for talking about their reproductive issues but now there is an increasing awareness all around the world about the importance of reproductive health and timely treatments. Women are now frequently visiting gynecologists and taking their reproductive health seriously. Women are now more open to taking treatments for painful menstruation cycles and going through a healthy pregnancy. Artificially induced labor is used by gynecologists to smoothen the process of childbirth for women and make it safer for both the parent and the infant. These factors will create promising opportunities for the application of prostaglandin the coming years.
"Increasing Cases of Glaucoma to Stimulate Growth in the Market"
The wave of digitization has swept up all industries across the world. All work today is done on computers, mobiles, or some type of electronic, digital device. The more people use electronic devices; the more strain it puts on their eyes. Excessive pressure on the eyes can be the cause of glaucoma. People over the age of sixty are also at a high risk of suffering glaucoma. Glaucoma is a disease that can even cause permanent vision loss and blindness. Prostaglandin is used in the treatment of glaucoma. As the number of people suffering from eye-related issues increases, the prostaglandin market is also anticipated to see an increase. The prostaglandin market growth is expected to rise greatly due to an increasing population suffering from ophthalmologic diseases.
Restraining Factors
"Dangers of Side-Effects of Prostaglandins may Inhibit Demand"
All medical treatments come with some side effects. While some side effects may not affect the normal life of the individual, there are some that can prove to be fatal to the life of the person. Prostaglandins also come with their own set of side effects. An increased amount of prostaglandins in the body can cause arthritis, which is the swelling of joints. Arthritis patients suffer from extreme pain in their bodies. Another side effect of prostaglandins is excessive menstrual cramping. While prostaglandins help in easing the pain from menstrual cramps, too many prostaglandins can become the cause of these cramps. A reduction in the amount of calcium in the body can also be used by prostaglandins which leads to brittle and weak bones. These factors may affect the market dynamics to some extent in the near future.
PROSTAGLANDIN MARKET REGIONAL INSIGHTS
- Request a Free sample to learn more about this report
Europe is the largest prostaglandin market due to growing awareness about prostaglandin. Healthcare facilities available in Europe are recognized to be some of the best in the world. Women’s health issues are also viewed without prejudice. Due to this, prostaglandin is increasingly used in healthcare institutions around Europe, for treating illnesses and injuries and for female reproductive health. Healthcare in Europe is also affordable and even free in some parts of Europe, which makes it more accessible to the population. Well-equipped hospital infrastructure and efficiency in the treatment is also a contributing factor to Europe leading the prostaglandin market.
North America holds the second-largest prostaglandin market share. North America is one of the most developed regions in the world, having top-notch healthcare facilities. People from around the world visit North America for treatments of various illnesses. It also has a high level of awareness of reproductive health issues. Due to these factors, North America commands a big market for prostaglandins.
Key Industry Players
"Key Players Focus on Partnerships to Gain a Competitive Advantage "
Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.
List of Market Players Profiled
- Sanofi CEPiA (France)
- Kyowa Hakko Pharma (Japan)
- Cayman Chemical (U.S.)
- Yonsung Fine Chemicals (South Korea)
- Johnson Matthey (U.K)
- Chirogate (Taiwan)
- Everlight Chemical (Taiwan)
- ANVI Pharma (India)
- AUSUN Pharmaceutical (China)
- Aspen Biopharma Labs (India)
Report Coverage
This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.
REPORT COVERAGE | DETAILS |
---|---|
Market Size Value In |
US$ 520.6 Million in 2022 |
Market Size Value By |
US$ 965.22 Million by 2031 |
Growth Rate |
CAGR of 7.1% from 2022 to 2031 |
Forecast Period |
2024-2031 |
Base Year |
2023 |
Historical Data Available |
Yes |
Segments Covered |
Type & Application |
Regional Scope |
Global |
Frequently Asked Questions
-
What value is the global prostaglandin market expected to touch by 2031?
The global prostaglandin market is expected to touch 965.22 million by 2031.
-
What CAGR is the prostaglandin market expected to exhibit by 2031?
The prostaglandin market is expected to exhibit a CAGR of 7.1% by 2031.
-
Which are the driving factors of the prostaglandin market?
The driving factors of the prostaglandin market are rising awareness of female reproductive health and increase in the cases of glaucoma.
-
Which are the top companies operating in the prostaglandin market?
Sanofi CEPiA, Kyowa Hakko Pharma, Cayman Chemical, Yonsung Fine Chemicals, Johnson Matthey, Chirogate, Everlight Chemical, ANVI Pharma, AUSUN Pharmaceutical, and Aspen Biopharma labs are the key companies operating in the prostaglandin market.